NCT02278991View on ClinicalTrials.gov

Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries

CompletedOBSERVATIONAL
Enrollment

149

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

October 2, 2018

Conditions
Peripheral Artery Disease
Interventions
DEVICE

Lutonix Drug Coated Balloon

Subject will receive treatment with the Lutonix Drug Coated Balloon

Trial Locations (12)

22527

Angiologikum Hamburg, Hamburg

23538

UKSH - Campus Lübeck, Lübeck

26504

University General Hospital of Patras, Pátrai

29549

Herz- und Gefäßzentrum Bad Bevensen, Bad Bevensen

34125

Klinikum Kassel, Kassel

59755

Klinikum Arnsberg, Arnsberg

79189

Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen

83022

RoMed Klinikum Rosenheim, Rosenheim

87509

Klinik Immenstadt, Immenstadt im Allgäu

92637

Klinikum Weiden, Weiden

96515

Gefäßzentrum Sonneberg, Sonneberg

38-500

SPZOZ Sanok, Sanok

Sponsors

Lead Sponsor

C. R. Bard
All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02278991 - Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries | Biotech Hunter | Biotech Hunter